InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
BRISBANE, Calif., Nov. 5, 2013 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 6,500,000 shares of its common stock at a price to the public of $13.00 per share in an underwritten public offering. InterMune has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock in connection with the offering. InterMune estimates net proceeds from the offering to be approximately $79.6 million (assuming no exercise of the underwriters' option to purchase additional shares of common stock), after deducting underwriting discounts and commissions and estimated offering expenses. InterMune intends to use the net proceeds from the offering to fund the commercialization of Esbriet® (pirfenidone) and its ASCEND clinical trial for U.S. registration of Esbriet, to advance the company's strategic initiatives including its new Esbriet formulations, its recently launched clinical trials supporting the use of Esbriet in idiopathic pulmonary fibrosis (IPF) and in potential new indications, its expanding anti-fibrotic research program with compounds intended to address IPF and other fibrotic diseases, and for general corporate purposes. InterMune expects to close this transaction on or about November 12, 2013, subject to satisfaction of customary closing conditions.
Goldman, Sachs & Co. and J. P. Morgan Securities LLC are acting as joint book-running managers of the offering. JMP Securities LLC, Leerink Swann LLC, UBS Securities LLC and Wells Fargo Securities, LLC are acting as co-managers of the offering. The offering is being conducted by means of a prospectus supplement filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on Form S-3. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Goldman, Sachs & Co. (Attn: Prospectus Department, 200 West Street, New York, New York 10282, Fax: 212-902-9316 or Email at firstname.lastname@example.org or by calling 1-866-471-2526) or J.P. Morgan Securities LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 866-803-9204). When available, electronic copies of the prospectus supplement may be obtained by visiting EDGAR on the SEC's website at http://www.sec.gov/.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended. Any offer, if at all, will be made only by means of a prospectus supplement and the accompanying prospectus, forming a part of the effective registration statement.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and specialty fibrotic diseases.
This news release contains forward-looking statements, including statements relating to InterMune's expectations regarding the completion, timing and size of the proposed public offering and its uses of proceeds from the proposed offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and InterMune cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that InterMune will be able to complete the public offering on the anticipated terms, or at all. If InterMune is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Additional risks and uncertainties relating to InterMune and its business can be found in the "Risk Factors" section of InterMune's preliminary prospectus supplement related to the public offering filed with the SEC on November 4, 2013, and in the prospectus supplement related to the proposed offering that InterMune expects to file with the SEC on or about November 6, 2013, and in its annual report on Form 10-K and quarterly reports on Form 10-Q filed with the SEC. InterMune undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in InterMune's expectations.
SOURCE InterMune, Inc.